Department of Medicine, University of California, San Francisco, San Francisco, CA, USA.
Am J Respir Crit Care Med. 2013 Aug 1;188(3):370-5. doi: 10.1164/rccm.201303-0522WS.
The National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health convened the Cell Therapy for Lung Disease Working Group on November 13-14, 2012, to review and formulate recommendations for future research directions. The workshop brought together investigators studying basic mechanisms and the roles of cell therapy in preclinical models of lung injury and pulmonary vascular disease, with clinical trial experts in cell therapy for cardiovascular diseases and experts from the NHLBI Production Assistance for Cell Therapy program. The purpose of the workshop was to discuss the current status of basic investigations in lung cell therapy, to identify some of the scientific gaps in current knowledge regarding the potential roles and mechanisms of cell therapy in the treatment of lung diseases, and to develop recommendations to the NHLBI and the research community on scientific priorities and practical steps that would lead to first-in-human trials of lung cell therapy.
美国国立卫生研究院(NIH)的国家心肺血液研究所(NHLBI)于 2012 年 11 月 13 日至 14 日召集了肺部疾病细胞治疗工作组,以审查和制定未来研究方向的建议。该研讨会汇集了研究基础机制和细胞治疗在肺损伤和肺血管疾病的临床前模型中作用的研究人员,以及心血管疾病细胞治疗临床试验专家和 NHLBI 细胞治疗生产援助计划的专家。研讨会的目的是讨论肺部细胞治疗的基础研究现状,确定目前关于细胞治疗在治疗肺部疾病中的潜在作用和机制的知识中的一些科学空白,并向 NHLBI 和研究界提出关于优先事项和科学步骤的建议,这些步骤将导致人类肺部细胞治疗的首次临床试验。